Biocon has announced the full integration of Biocon Biologics Limited (BBL) as a wholly-owned subsidiary, following a strategic share swap. For the fiscal year ended March 31, 2026, the company reported a consolidated revenue of Rs. 1,69,270 million. The board has also recommended a final dividend of Rs. 0.50 per share. Additionally, the company announced significant board-level changes, a new long-term incentive plan, and the appointment of new statutory auditors.
Financial Highlights
Biocon reported a strong financial performance for the fiscal year ended March 31, 2026. On a consolidated basis, the company achieved total revenue of Rs. 1,69,270 million, compared to Rs. 1,52,617 million in the previous year. The consolidated net profit for the year stood at Rs. 3,688 million.
Strategic Integration of Biocon Biologics
In a significant corporate move, Biocon has approved the acquisition of the remaining ~2% equity stake in its material subsidiary, Biocon Biologics Limited (BBL). This move transitions BBL into a wholly-owned subsidiary. The acquisition is being executed via a share swap, involving the issuance of up to 87,92,317 equity shares of Biocon at a price of Rs. 376.16 per share to eligible BBL shareholders. This integration aims to simplify the corporate structure, unify capital allocation strategies, and unlock operational synergies.
Dividend and Governance Updates
The Board has recommended a final dividend of 10%, amounting to Rs. 0.50 per equity share of face value Rs. 5, for the financial year ended March 31, 2026. The record date for this dividend is set for Friday, July 03, 2026.
Regarding corporate governance, the company announced the appointment of M/s. S. R. Batliboi & Associates LLP as the new Statutory Auditors for a five-year term, effective from the conclusion of the 48th Annual General Meeting (AGM). Furthermore, the Board has approved several key leadership appointments, including the designation of Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer – Emerging Markets and Head of Global API & Global BD, both as Senior Management Personnel.
Future Outlook and Incentive Plans
To align with its growth strategy, the Board has approved the Biocon Unity Long Term Incentive Plan 2026. This plan encompasses various equity-based incentives, including stock options, performance stock units, and restricted stock units, designed to reward and retain eligible employees across the company and its subsidiaries. The 48th AGM is scheduled to be held on Thursday, August 06, 2026, via video conferencing.
Source: BSE
